Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Biomater Sci. 2021 Oct 12;9(20):6903-6914. doi: 10.1039/d1bm00685a.
Abdominal aortic aneurysm (AAA) is associated with the loss of vascular smooth muscle cells (SMCs) within the vessel wall. Direct delivery of therapeutic cells is challenging due to impaired mechanical integrity of the vessel wall. We hypothesized that porous collagen scaffolds can be an effective vehicle for the delivery of human-derived SMCs to the site of AAA. The purpose was to evaluate if the delivery of cell-seeded scaffolds can abrogate progressive expansion in a mouse model of AAA. Collagen scaffolds seeded with either primary human aortic SMCs or induced pluripotent stem cell derived-smooth muscle progenitor cells (iPSC-SMPs) had >80% cell viability and >75% cell penetrance through the scaffold's depth, while preserving smooth muscle phenotype. The cell-seeded scaffolds were successfully transplanted onto the murine aneurysm -adventitia on day 7 following AAA induction using pancreatic porcine elastase infusion. Ultrasound imaging revealed that SMC-seeded scaffolds significantly reduced the aortic diameter by 28 days, compared to scaffolds seeded with iPSC-SMPs or without cells (acellular scaffold), respectively. Bioluminescence imaging demonstrated that both cell-seeded scaffold groups had cellular localization to the aneurysm but a decline in survival with time. Histological analysis revealed that both cell-seeded scaffold groups had more SMC retention and less macrophage invasion into the medial layer of AAA lesions, when compared to the acellular scaffold treatment group. Our data suggest that scaffold-based SMC delivery is feasible and may constitute a platform for cell-based AAA therapy.
腹主动脉瘤 (AAA) 与血管壁内血管平滑肌细胞 (SMCs) 的丧失有关。由于血管壁的机械完整性受损,直接输送治疗细胞具有挑战性。我们假设多孔胶原支架可以成为向 AAA 部位输送人源性 SMC 的有效载体。目的是评估细胞接种支架的输送是否可以阻止 AAA 小鼠模型中进行性扩张。用原代人主动脉 SMC 或诱导多能干细胞衍生的平滑肌祖细胞 (iPSC-SMP) 接种的胶原支架的细胞存活率>80%,细胞穿透深度>75%,同时保持平滑肌表型。在用胰蛋白酶原弹性蛋白酶输注诱导 AAA 后第 7 天,成功地将细胞接种支架移植到小鼠动脉瘤-外膜上。超声成像显示,与 iPSC-SMP 接种的支架或无细胞(无细胞支架)相比,SMC 接种的支架分别在 28 天内显著减小了主动脉直径。生物发光成像显示,两组细胞接种支架均在动脉瘤处具有细胞定位,但随时间推移存活率下降。组织学分析显示,与无细胞支架治疗组相比,两组细胞接种支架均保留了更多的 SMC,并减少了巨噬细胞侵入 AAA 病变的中膜层。我们的数据表明,基于支架的 SMC 输送是可行的,可能构成基于细胞的 AAA 治疗的平台。